DWTX

Dogwood Therapeutics, Inc. NASDAQ Listed Dec 17, 2020

Healthcare ·Biotechnology ·US · dwtx.com

$1.56

Mkt Cap $3.0M

52w Low $1.28 3.4% of range 52w High $9.50

50d MA $2.21 200d MA $4.24

P/E (TTM) -0.3x

EV/EBITDA -1.0x

P/B 0.2x

Debt/Equity 0.0x

ROE -45.7%

P/FCF -2.2x

RSI (14) —

ATR (14) —

Beta 2.07

50d MA $2.21

200d MA $4.24

Avg Volume 81.0K

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

SIC Code

2834

CIK (SEC)

1818844

Phone

866 620 8655

44 Milton Avenue · Alpharetta, GA 30009 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 7, 2026	BMO	—	—	—	1.65	-0.6%	-5.5%	+5.8%	—	—	—	—
Mar 18, 2026	AMC	-0.86	-0.26	+69.8%	2.97	-2.4%	-8.4%	+10.3%	-7.3%	-6.8%	-10.8%	—
Nov 6, 2025	AMC	-1.23	-8.20	-566.7%	5.20	+0.6%	+1.2%	+5.7%	+1.4%	+3.4%	-6.3%	—
Aug 13, 2025	AMC	-1.26	-1.99	-57.9%	4.80	+1.9%	+2.5%	+0.2%	+7.5%	-9.2%	+1.0%	—
May 8, 2025	AMC	-0.77	-4.21	-446.8%	4.56	-2.0%	+0.0%	+4.8%	+1.5%	+0.0%	+13.2%	—
Feb 26, 2025	AMC	-1.36	-5.90	-333.6%	5.12	-2.0%	-8.0%	+1.7%	-10.4%	-3.3%	+7.2%	—
Nov 7, 2024	AMC	-1.18	-2.05	-73.7%	4.45	+0.7%	-3.4%	-20.5%	+1.2%	-14.2%	+7.7%	—
Aug 8, 2024	AMC	-0.07	-0.05	+28.6%	4.47	+4.0%	-2.0%	-4.6%	+7.7%	-2.2%	+7.3%	—
May 9, 2024	AMC	-0.08	-0.07	+12.5%	9.32	-1.5%	-4.7%	-0.3%	+7.9%	+6.6%	-5.2%	—
Dec 31, 2023	AMC	-1.75	-1.43	+18.2%	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	-2.25	-1.62	+28.1%	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	-1.25	-1.96	-56.5%	34.50	+2.9%	-1.4%	-4.4%	+10.8%	+0.7%	+4.8%	—
Mar 31, 2023	AMC	-4.00	-2.07	+48.3%	9.20	-2.9%	-2.0%	-4.1%	+14.5%	+5.1%	+31.5%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.38	$1.35	-2.2%	-2.9%	+0.7%	+0.0%	+5.9%	+2.1%
Feb 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.91	$3.01	+3.4%	+0.7%	-6.1%	+1.8%	+2.5%	-3.8%
Jan 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.90	$2.86	-1.4%	-3.8%	+5.0%	+3.4%	+1.7%	+2.9%
Sep 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.91	$7.88	-0.4%	-2.7%	-8.2%	-9.2%	-0.2%	+4.4%
Apr 23	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$5.46	$5.72	+4.8%	+7.5%	-3.6%	-2.3%	+1.1%	-3.2%

Data updated apr 25, 2026 6:06am · Source: massive.com